Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 37%.
Reasons for caution
- Similar past buys beat the S&P 500 only 48% of the time (419 cases); the typical one trailed it by 1.2%.
What happened after this filing
Insider Twins: past buys with the same traits
1 insider buying · no CEO or CFO · $1M+ · stock down 0–20% in 3 months
KXIN Jul 21, 2020 +836.6% vs S&PFSLY Apr 2, 2020 +355.1% vs S&PKOD Aug 21, 2020 +174.0% vs S&PMIST Mar 19, 2020 -98.9% vs S&PBNR Apr 2, 2026 -58.7% vs S&PPAR Jan 7, 2026 -56.9% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Prem S. Shah (an officer) bought $2.0M of CVS at about $83.89 on Nov 6, 2026, reported to the SEC on Nov 6, 2026. Buys like this beat the S&P 500 48% of the time since 2020, against 46% for all insider buys. We found 2 points that make it worth a closer look and 1 reason for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the CVS alerts below.
Get this week's insider report
The week's biggest insider buys, every new cluster buy and the stocks to watch, in one printable PDF. Plus the free Monday email.
Check your inbox to confirm, so you get next week's report too.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.